News

March 26, 2019

Collaboration to Explore How Gut Bacteria Might Bolster Immunotherapy

News

Seres Therapeutics and AstraZeneca have established a research collaboration to unravel the mechanisms by which the microbiome – the natural, beneficial community of microbes living in the gut — might ... Read more

March 22, 2019

FDA Approves Tecentriq/Chemo for Newly Diagnosed Extensive-stage SCLC

News

The U.S. Food and Drug Administration has approved the use of Tecentriq (atezolizumab) in combination with the chemotherapies Paraplatin (carboplatin) and etoposar for the initial treatment of extensive-stage small-cell lung cancer ... Read more

March 20, 2019

EU Approves Keytruda/Chemo Combo to Treat Metastatic Squamous NSCLC

News

The European Commission has approved a combination of Keytruda (pembrolizumab) plus standard chemotherapy for the initial treatment of metastatic squamous non-small cell lung cancer (NSCLC), Merck (known as MSD outside ... Read more

March 19, 2019

Alligator Bioscience Starts Phase 1 Trial to Test ATOR-1015 in Advanced Solid Tumors

News

The first patient has been dosed in Alligator Bioscience’s Phase 1 clinical trial testing the investigational immunotherapy ATOR-1015 as a new treatment for advanced solid tumors, the company announced. The open-label trial ... Read more

March 15, 2019

TC BioPharm, Trinity College Dublin Pair to Develop Cancer-fighting Cell Therapy

News

TC BioPharm (TCB) and Trinity College Dublin researchers are working together to expedite the production of V delta 1 γδ T cells to be used in the fight against solid tumors. TCB’s ... Read more

March 13, 2019

Immune Checkpoint Inhibitors Safe, Effective in HIV-positive Patients with Advanced Cancer, Research Reveals

News

Immune checkpoint inhibitors may be safe and effective in advanced cancer patients with human immunodeficiency virus (HIV), according to a review study. The research, “Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients ... Read more

March 12, 2019

Subtypes of Immune Cells in Tumor Environment Can Predict Follicular Lymphoma Response to Therapy

News

The presence of specific subtypes of immune cells in the tumor environment of people with follicular lymphoma can predict how a patient’s immune system will respond to the disease, as ... Read more

March 8, 2019

Phase 3 Keytruda Trial Fails Primary Objectives in Liver Cancer Patients Who Received Prior Nexavar

News

Immune checkpoint inhibitor Keytruda (pembrolizumab) did not significantly improve the survival outcomes of previously treated hepatocellular carcinoma patients on best supportive care, results from a Phase 3 trial show. While ... Read more

March 6, 2019

FDA Places Partial Hold on Xencor’s Phase 1 Trial of XmAb14045 Immunotherapy for Blood Cancers

News

The U.S. Food and Drug Administration has placed a partial clinical hold on Xencor’s Phase 1 clinical trial of XmAb14045 for acute myeloid leukemia and other CD123-positive blood cancers because of ... Read more

March 5, 2019

FDA Grants Priority Review to Keytruda for Advanced Small Cell Lung Cancer

News

The U.S. Food and Drug Administration has accepted Merck‘s application seeking accelerated approval of Keytruda (pembrolizumab) for the treatment of advanced small cell lung cancer (SCLC) patients who failed at least two prior therapies. ... Read more